Amaç: Bu çalışmanın amacı, Tip 2 diyabet (DM) hastalarında morbidite ve mortaliteye neden olan, diyabetin mikrovasküler, yaygın ve önlenebilir komplikasyonlarından biri olan diyabetik nöropatide (DN) sistemik inflamatuar indekslerin araştırılmasıdır. Gereç ve Yöntemler: Tip 2 DM’li 414 hasta DN varlığına göre 2 gruba ayrıldı. Her 2 grupta hastaların serum trombosit, lenfosit, monosit sayıları, nötrofil/ lenfosit oranı [neutrophil/lymphocyte ratio (NLR)], trombosit/lenfosit oranı [platelet/lymphocyte ratio (PLR)], monosit/lenfosit oranları [monocyte/lymphocyte ratios (MLR)], sistemik inflamatuar indeks [systemic inflammatory index (SII)], sistemik inflamatuar yanıt indeksi [systemic inflammatory response index (SIRI)], Hemoglobin A1c (HbA1c) seviyeleri değerlendirildi. Bulgular: Her 2 grupta yaş ve cinsiyet açısından farklılık saptanmadı. Çalışmaya DN semptom ve bulguları olan 207 DM’li hasta ile nöropati semptom ve bulguları olmayan 207 DM’li hasta dâhil edildi. Her 2 grup karşılaştırdığında DN grubunda SII, SIRI, HbA1c düzeyi ve NLR oranında istatistiksel anlamlı yükseklik saptandı (p<0,001). SII ile SIRI ve HbA1c düzeyi arasında pozitif korelasyon bulundu. DN varlığını tespit etmede SII’nin duyarlılığı ve özgüllüğü sırasıyla %71,69 ve %83,33 idi. SIRI için duyarlılık %69,04 ve özgüllük %62,22 idi. Sonuç: DN pozitif grupta ucuz olan ve rutin kan testlerinde kolaylıkla hesaplanabilen sistemik inflamasyon parametrelerindeki yükselme, nöropati gibi kronik mikrovasküler hastalık varlığının öngörülmesinde yardımcı olabilir.

Objective: The aim of this study was to investigate systemic inflammatory indices in diabetic neuropathy (DN), which is one of the microvascular, common and preventable complications of diabetes that causes morbidity and mortality in Type 2 Diabetes Mellitus (DM) patients. Material and Methods: A total of 414 patients with DM were divided into 2 groups according to the presence of DN. Platelet, lymphocyte, monocyte counts, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratios (MLR), systemic inflammatory index (SII), systemic inflammatory response index (SIRI), and hemoglobin A1c (HbA1c) levels were analyzed in each group. Results: No difference was found in both groups in terms of age and gender. A total of 207 patients with DN and 207 patients with DM without DN symptoms and findings were included in the study. When the 2 groups were compared, a statistically significant increase in lSII, SIRI, HbA1c level and NLR rate was detected in the DN group (p<0.001). A positive correlation was found between SII and SIRI and the HbA1c level. The sensitivity and specificity were 71.69% and 83.33%, respectively, for SII in detecting DN. For SIRI, the sensitivity was 69.04% and the specificity was 62.22%. Conclusion: In the DN-positive group, this elevation in systemic inflammation parameters, which are inexpensive and can be easily calculated in routine blood tests, may be helpful in predicting the presence of chronic microvascular disease such as neuropathy.

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14. [Crossref]  [PubMed] 
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. [Crossref]  [PubMed] 
3. Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016;16:29. [Crossref]  [PubMed]  [PMC] 
4. Jin HY, Park TS. Role of inflammatory biomarkers in diabetic peripheral neuropathy. J Diabetes Investig. 2018;9(5):1016-8. [Crossref]  [PubMed]  [PMC] 
5. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900-17. [Crossref]  [PubMed]  [PMC] 
6. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11:738-49. [Crossref]  [PubMed]  [PMC] 
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46. [Crossref]  [PubMed] 
8. Pitsavos C, Tampourlou M, Panagiotakos DB, et al. Association between low-grade systemic ınflammation and Type 2 diabetes mellitus among men and women from the ATTICA study. Rev Diabet Stud. 2007;4:98-104. [Crossref]  [PubMed]  [PMC] 
9. Peirovy A, Malek Mahdavi A, Khabbazi A, et al. Clinical usefulness of hematologic indices as predictive parameters for systemic lupus erythematosus. Lab Med. 2020;51:519-28. [Crossref]  [PubMed] 
10. Hao X, Li D, Wu D, et al. The Relationship between Hematological Indices and Autoimmune Rheumatic Diseases (ARDs), a meta-Analysis. Sci Rep. 2017;7:10833. [Crossref]  [PubMed]  [PMC] 
11. Yang Z, Zhang Z, Lin F, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS. 2017;125:863-71. [Crossref]  [PubMed] 
12. Ayna AB, Ermurat S, Coşkun BN, et al. Neutrophil to lymphocyte ratio and mean platelet volume as inflammatory indicators in systemic lupus erythematosus nephritis. Arch Rheumatol. 2016;32:21-5. [Crossref]  [PubMed]  [PMC] 
13. Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018;65:503-10. [Crossref]  [PubMed] 
14. Xie QK, Chen P, Hu WM, et al. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med. 2018;16:273. [Crossref]  [PubMed]  [PMC] 
15. Erdoğan M, Erdöl MA, Öztürk S, et al. Systemic immune-inflammation index is a novel marker to predict functionally significant coronary artery stenosis. Biomark Med. 2020;14:1553-61. [Crossref]  [PubMed] 
16. Liu Y, Ye T, Chen L, et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coron Artery Dis. 2021;32:715-20. [Crossref]  [PubMed] 
17. Candemir M, Kiziltunç E, Nurkoç S, et al. Relationship between systemic immune-inflammation index (SII) and the severity of stable coronary artery disease. Angiology. 2021;72:575-81. [Crossref]  [PubMed] 
18. Huang J, Zhang Q, Wang R, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit. 2019;25:9690-701. [Crossref]  [PubMed]  [PMC] 
19. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-22. [Crossref]  [PubMed] 
20. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147-57. [Crossref]  [PubMed] 
21. Yang R, Chang Q, Meng X, et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9:3295-302. [Crossref]  [PubMed]  [PMC] 
22. Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261-72. [Crossref]  [PubMed]  [PMC] 
23. Geng Y, Shao Y, Zhu D, et al. Systemic Immune-Inflammation Index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. Sci Rep. 2016;6:39482. [Crossref]  [PubMed]  [PMC] 
24. Hong X, Cui B, Wang M, et al. Systemic Immune-inflammation Index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236:297-304. [Crossref]  [PubMed] 
25. Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018;38:BSR20180172. [Crossref]  [PubMed]  [PMC] 
26. Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018;38:BSR20180172. [Crossref]  [PubMed]  [PMC] 
27. Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med. 2011;17:1381-90. [Crossref]  [PubMed]  [PMC] 
28. Shanmugam N, Reddy MA, Guha M, et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003;52:1256-64. [Crossref]  [PubMed] 
29. Guha M, Bai W, Nadler JL, et al. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem. 2000;275:17728-39. [Crossref]  [PubMed] 
30. Hofmann MA, Schiekofer S, Kanitz M, et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care. 1998;21:1310-6. [Crossref]  [PubMed] 
31. Kedziora-Kornatowska KZ. Production of superoxide and nitric oxide by granulocytes in non-insulin-dependent diabetic patients with and without diabetic nephropathy. IUBMB Life. 1999;48:359-62. [Crossref]  [PubMed] 
32. Korpinen E, Groop PH, Fagerudd JA, et al. Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with Type 1 diabetes mellitus with diabetic nephropathy. Diabet Med. 2001;18:121-5. [Crossref]  [PubMed] 
33. Doupis J, Lyons TE, Wu S, et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157-63. [Crossref]  [PubMed]  [PMC] 
34. Magrinelli F, Briani C, Romano M, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;2015:547834. [Crossref]  [PubMed]  [PMC] 
35. Herder C, Kannenberg JM, Huth C, et al. Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Diabetes Care. 2017;40(4):569-76. [Crossref]  [PubMed] 
36. Hussain G, Rizvi SA, Singhal S, et al. Serum levels of TNF-α in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:238-42. [Crossref]  [PubMed] 
37. Roumeliotis S, Neofytou IE, Maassen C, et al. Association of red blood cell distribution width and neutrophil-to-lymphocyte ratio with calcification and cardiovascular markers in chronic kidney disease. Metabolites. 2023;13:303. [Crossref]  [PubMed]  [PMC] 
38. Halmaciu I, Arbănași EM, Kaller R, et al. Chest CT severity score and systemic inflammatory biomarkers as predictors of the need for invasive mechanical ventilation and of COVID-19 patients' mortality. Diagnostics (Basel). 2022;12:2089. [Crossref]  [PubMed]  [PMC] 
39. Mureșan AV, Russu E, Arbănași EM, et al. The predictive value of nlr, mlr, and plr in the outcome of end-stage kidney disease patients. Biomedicines. 2022;10:1272. [Crossref]  [PubMed]  [PMC] 
40. Mureșan AV, Hălmaciu I, Arbănași EM, et al. Prognostic Nutritional Index, Controlling Nutritional Status (CONUT) Score, and inflammatory biomarkers as predictors of deep vein thrombosis, acute pulmonary embolism, and mortality in COVID-19 patients. Diagnostics (Basel). 2022;12:2757. [Crossref]  [PubMed]  [PMC] 
41. Arbănași EM, Mureșan AV, Coșarcă CM, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio impact on predicting outcomes in patients with acute limb ischemia. Life (Basel). 2022;12:822. [Crossref]  [PubMed]  [PMC] 
42. Melinte RM, Arbănași EM, Blesneac A, et al. Inflammatory biomarkers as prognostic factors of acute deep vein thrombosis following the total knee arthroplasty. Medicina (Kaunas). 2022;58:1502. [Crossref]  [PubMed]  [PMC]